Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Verici DxLSE:VRCI EBIT per Share is £-0.01 as of Dec. 2025. The stock has 3 warning signs investors should review. Among 165 Medical Diagnostics & Research companies, Verici Dx ranks better than 84.24% on this metric.
Verici Dx's EBIT per Share for the
six
months ended in Dec. 2025 was £-0.00.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was £-0.01.
During the past 3 years, the average EBIT per Share Growth Rate was 50.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Verici Dx's EBIT per Share or its related term are showing as below:
LSE:VRCI'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 21.9 Med: 36.1 Max: 50.3
Current: 50.3
During the past 6 years, the highest 3-Year average EBIT per Share Growth Rate of Verici Dx was 50.30% per year. The lowest was 21.90% per year. And the median was 36.10% per year.
LSE:VRCI's 3-Year EBIT Growth Rate is ranked better than 84.24% of 165
companies
in the Medical Diagnostics & Research industry
Industry Median: 13.2
vs LSE:VRCI: 50.30
Verici Dx's EBIT for the
six
months ended in Dec. 2025 was £-2.86 Mil.
Verici Dx (LSE:VRCI) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Verici Dx EBIT per Share Related Terms
Verici Dx EBIT per Share Historical Data
* Premium members only.
The historical data trend for Verici Dx's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was £-0.01
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Verici Dx (LSE:VRCI) has a EBIT per Share of £-0.01 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Verici Dx and its competitors. According to the industry distribution chart, Verici Dx ranks #26 out of 165 companies in the Medical Diagnostics & Research industry, placing it in the top 15.8%.
Is Verici Dx's EBIT per Share too high?
Verici Dx's current EBIT per Share is £-0.01. Based on the distribution chart, Verici Dx ranks #26 out of 165 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers.
How does Verici Dx's EBIT per Share compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Verici Dx ranks #26 out of 165 companies for EBIT per Share. This places Verici Dx in the top 16% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 13.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Diagnostics & Research company?
The median EBIT per Share among Medical Diagnostics & Research companies is 13.20, based on 165 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Verici Dx and its competitors. For the Medical Diagnostics & Research industry, the median EBIT per Share is 13.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Verici Dx's current EBIT per Share is £-0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Verici Dx stock overvalued right now?
Verici Dx (LSE:VRCI) has a current EBIT per Share of £-0.01. The current EBIT per Share is £-0.01. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Verici Dx (LSE:VRCI), the current EBIT per Share is £-0.01 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Verici Dx PLC is an immuno-diagnostics development company. The company is focused on the development of prognostic and diagnostic tests for kidney transplant patients. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; Tuteva, a post-transplant diagnostic focused upon acute cellular rejection, including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels; and Protega will utilize RNA gene signatures to more accurately risk stratify outcome from fibrosis in a transplant patient. The business of the Group comprises a single activity, which of the development of prognostic and diagnostic tests for kidney transplant patients.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:VRCI has been successfully added to your 
